Literature DB >> 29636813

Refractory severe immune thrombocytopenia in a twin pregnancy.

Patrick Harrington1, Catherine Nelson-Piercy1, Catherine Williamson2, Nichola Cooper3, Rachel Kesse-Adu1, Susan Robinson1.   

Abstract

A 34-year-old woman presented at 29 weeks gestation of a twin pregnancy, with a platelet count of 1 × 109/l. She was extensively investigated and was subsequently diagnosed with severe immune thrombocytopenia. She did not respond to initial treatment with corticosteroids and intravenous immunoglobulin. She also failed to respond to second-line therapies of Anti-D immunoglobulin, Azathioprine and the thrombopoietin agonist Romiplostim. Her case was further complicated by an episode of obstetric cholestasis possibly related to Azathioprine treatment. She went on to require plasma exchange around the time of an elective Caesarean section which provided temporary improvement in the platelet count and enabled safe delivery. This case highlights some of the challenges faced in the management of patients with severe and refractory immune thrombocytopenia during pregnancy.

Entities:  

Keywords:  Haematology; high-risk pregnancy; immunology; multiple pregnancy

Year:  2017        PMID: 29636813      PMCID: PMC5888838          DOI: 10.1177/1753495X17709188

Source DB:  PubMed          Journal:  Obstet Med        ISSN: 1753-495X


  15 in total

1.  Teratogen update: azathioprine and 6-mercaptopurine.

Authors:  Janine E Polifka; J M Friedman
Journal:  Teratology       Date:  2002-05

2.  Intravenous anti-D immunoglobulin in the treatment of resistant immune thrombocytopenic purpura in pregnancy.

Authors:  K Sieunarine; S Shapiro; M J Al Obaidi; J Girling
Journal:  BJOG       Date:  2007-02-19       Impact factor: 6.531

Review 3.  Toxicities of the thrombopoietic growth factors.

Authors:  Adam Cuker
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

4.  Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy.

Authors:  Justine Decroocq; Louis Marcellin; Camille Le Ray; Lise Willems
Journal:  Obstet Gynecol       Date:  2014-08       Impact factor: 7.661

5.  Immunosuppressive drugs and the foetus.

Authors:  H V Price; J R Salaman; K M Laurence; H Langmaid
Journal:  Transplantation       Date:  1976-04       Impact factor: 4.939

6.  A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura.

Authors:  G C Newman; M V Novoa; E M Fodero; M L Lesser; B M Woloski; J B Bussel
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

7.  Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus.

Authors:  J K Alkaabi; S Alkindi; N Al Riyami; F Zia; L M A Balla; S M Balla
Journal:  Lupus       Date:  2012-12       Impact factor: 2.911

8.  Combined plasma exchange and platelet transfusion in immune-mediated thrombocytopenic emergencies.

Authors:  Laura Finn; Han Tun
Journal:  Transfus Apher Sci       Date:  2013-07-12       Impact factor: 1.764

9.  Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy.

Authors:  Marc Michel; Maria V Novoa; James B Bussel
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

10.  Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study.

Authors:  Victoria Geenes; Lucy C Chappell; Paul T Seed; Philip J Steer; Marian Knight; Catherine Williamson
Journal:  Hepatology       Date:  2014-02-26       Impact factor: 17.425

View more
  1 in total

1.  Effect of Thrombopoietin Receptor Agonist on Pregnant Mice.

Authors:  Kensaku Nakai; Takuya Misugi; Kohei Kitada; Yasushi Kurihara; Mie Tahara; Akihiro Hamuro; Akemi Nakano; Masayasu Koyama; Yukimi Kira; Daisuke Tachibana
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.